Detalles de la búsqueda
1.
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
Rheumatology (Oxford)
; 60(1): 113-124, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32584415
2.
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
Ann Rheum Dis
; 79(7): 920-928, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32381562
3.
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.
Ann Rheum Dis
; 77(5): 699-705, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29343510
4.
An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson's disease.
J Neural Transm (Vienna)
; 125(6): 953-963, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29484495
5.
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
Rheumatology (Oxford)
; 56(9): 1498-1509, 2017 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28498975
6.
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
BMC Neurol
; 16: 90, 2016 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27267880
7.
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
BMC Neurol
; 15: 17, 2015 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-25879416
8.
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.
RMD Open
; 10(2)2024 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38724259
9.
Transdermal rotigotine for the perioperative management of restless legs syndrome.
BMC Neurol
; 12: 106, 2012 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-23009552
10.
Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study.
Mediterr J Rheumatol
; 33(Suppl 1): 162-172, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36127922
11.
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.
ACR Open Rheumatol
; 4(9): 794-801, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35733363
12.
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.
RMD Open
; 8(1)2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35296532
13.
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review.
Rheumatol Ther
; 9(6): 1481-1497, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36178585
14.
Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
Arthritis Res Ther
; 23(1): 274, 2021 10 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34715908
15.
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study.
Ther Adv Musculoskelet Dis
; 13: 1759720X211003803, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33854572
16.
Lack of association between antimyelin antibodies and progression to multiple sclerosis.
N Engl J Med
; 356(4): 371-8, 2007 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-17251533
17.
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
RMD Open
; 6(1)2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32371433
18.
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE.
Rheumatol Ther
; 7(3): 581-599, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32529495
19.
Subtraction MR images in a multiple sclerosis multicenter clinical trial setting.
Radiology
; 250(2): 506-14, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19037018
20.
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.
BMC Neurol
; 9: 19, 2009 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19457248